Literature DB >> 30336770

Gastroduodenal Disorders in Patients with CVID Undergoing Immunoglobulin Therapy.

Gilda Varricchi1,2,3, Antonio Pecoraro1,2,3, Ludovica Crescenzi1,2,3, Giancarlo Marone4,5, Antonio Travaglino6, Francesco Paolo D'Armiento6, Arturo Genovese1,2,3, Giuseppe Spadaro1,2,3.   

Abstract

BACKGROUND: Common variable immunodeficiency (CVID) encompasses a heterogeneous group of primary antibody deficiency disorders characterized by recurrent infections, autoimmunity and malignancies. Gastrointestinal manifestations are frequently associated with CVID.
OBJECTIVE: In this cross-sectional study, we evaluated gastric and duodenal involvement in a cohort of adult patients with CVID.
METHODS: Upper gastrointestinal endoscopy was performed in 58 patients (26 males, mean age 47.8±15.6 years), diagnosed with CVID according to 2014 ESID criteria. Random biopsies were collected from gastric antrum and descending duodenum for the all enrolled subjects. Intraepithelial lymphocytosis in descending duodenum was defined as the presence of 25 lymphocytes per 100 enterocytes.
RESULTS: The major histopathological findings that we found were: a) chronic active gastritis (44.8%), Helicobacter pylori-associated (8.6%), b) chronic duodenitis (39.6%) with intraepithelial lymphocytosis (31%) and absence of plasma cells (18.9%) and c) autoimmune atrophic gastritis (5.2%). Three patients (5.2%) presented Intestinal Metaplasia (IM) of the gastric antrum. This finding was associated with H. pylori infection and persisted after the eradication in one patient. IM was associated with autoimmune atrophic gastritis in two cases. Giardia lamblia infection was observed in the duodenum samples from three patients (5.2%). A diagnosis of Gastric adenocarcinoma was made in a 58-year- old woman diagnosed with gastric dysplasia one year earlier.
CONCLUSION: In our cohort of CVID patients, gastro-duodenal histopathological findings, including malignancies, are frequent and can affect long-term prognosis. A rigorous endoscopic follow-up is needed in CVID patients irrespective of the gastrointestinal symptoms. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  CVID; Giardia lamblia; Helicobacter pylori; IELs; duodenitis; gastritis; immunodeficiency; immunoglobulin therapy.

Mesh:

Year:  2018        PMID: 30336770     DOI: 10.2174/1389201019666181010170630

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  5 in total

1.  [Common variable immune deficiency in adult patients: analysis of 13 cases and literature review].

Authors:  Shenglan Gong; Yin Pu; Lingli Xie; Xiaoya Yang; Hui Mao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-08-30

Review 2.  Immunogenetics of gastrointestinal cancers: A systematic review and retrospective survey of inborn errors of immunity in humans.

Authors:  Beishi Zheng; Michael G Artin; Howard Chung; Bing Chen; Siming Sun; Benjamin L May; Chin Hur; Peter H R Green; Timothy C Wang; Jiheum Park; Xiao-Fei Kong
Journal:  J Gastroenterol Hepatol       Date:  2022-04-13       Impact factor: 4.369

Review 3.  Gut Microbiome and Common Variable Immunodeficiency: Few Certainties and Many Outstanding Questions.

Authors:  Gilda Varricchi; Remo Poto; Gianluca Ianiro; Alessandra Punziano; Gianni Marone; Antonio Gasbarrini; Giuseppe Spadaro
Journal:  Front Immunol       Date:  2021-08-02       Impact factor: 7.561

4.  Common variable immunodeficiency: different faces of the same disease.

Authors:  Elżbieta Grześk; Anna Dąbrowska; Anna Urbañczyk; Marlena Ewertowska; Mariusz Wysocki; Sylwia Kołtan
Journal:  Postepy Dermatol Alergol       Date:  2021-11-05       Impact factor: 1.837

Review 5.  Heterogeneity of Liver Disease in Common Variable Immunodeficiency Disorders.

Authors:  Antonio Pecoraro; Ludovica Crescenzi; Gilda Varricchi; Giancarlo Marone; Giuseppe Spadaro
Journal:  Front Immunol       Date:  2020-02-28       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.